To perform assay development and validation, we utilized healthy donor blood spiked with cancer cell lines representing three major and diverse breast cancer subtypes: triple-negative (BT-20), ER+ (MCF7) and HER2+ (SK-BR-3). This evidence concerns the gene ESR1 and breast carcinoma.